PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript Summary
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.The following is a summary of the PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript:
以下是PetVivo Holdings, Inc. (PETV) 2025年第二季度業績會議記錄總結：
Financial Performance:
財務表現：
PetVivo reported a sequential revenue growth of 62% in the fiscal second quarter, primarily driven by a 147% increase in distributor sales.
The company achieved a gross profit margin of 89.5%.
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.
Operating expenses declined by 25% due to strategic company-wide reduction and restructuring programs.
PetVivo報告，由經銷商銷售增長147％主導，公司第二季度財政營業收入環比增長62％。
公司的毛利潤率達到89.5％。
淨虧損較去年的370萬美元顯著改善，本季度降至220萬美元。
由於戰略性全公司減少和重組計劃，營業費用下降了25％。
Business Progress:
業務進展：
PetVivo expanded the distribution of its flagship product, Spryng, which has now reached over 800 clinics across all 50 states.
New clinical trials, including an elbow study for dogs with osteoarthritis, are underway, enhancing the product's validation and adoption.
Significant staffing increases in sales and marketing roles have been made to support growth, especially aimed at the companion animal market.
PetVivo participated in major veterinary conferences and events, boosting visibility and advocacy for its Spryng product among veterinary professionals.
PetVivo擴大了旗艦產品Spryng的分銷範圍，目前已覆蓋50個州的800多家診所。
新的臨床試驗，包括關於患有骨關節炎的狗的肘部研究正在進行中，將增強該產品的驗證和採用。
已經加大了銷售和市場營銷崗位的重要人員配備，以支持增長，特別是針對伴侶動物市場。
PetVivo參加了主要的獸醫會議和活動，提升了Spryng產品在獸醫專業人士中的知名度和推廣。
Opportunities:
機會：
The expansion into the companion animal market, a significantly larger market segment, aims at driving future revenue growth.
Continued collaboration with leading R&D companies, like Orthobiologic Innovations, for product development and clinical trials to enhance product adoption.
進軍伴侶動物市場，這一規模顯著較大的市場細分，旨在推動未來營業收入增長。
與Orthobiologic Innovations等領先的研發公司繼續合作，以進行產品開發和臨床試驗，以增強產品的採用。
Risks:
風險：
Transition from smaller equine markets to companion animal markets involves risk of market acceptance and operational adjustments.
從較小的馬匹市場轉向伴侶動物市場，涉及市場接受風險和運營調整。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
